TY - JOUR
T1 - Sickle Cell Disease
T2 - Current Drug Treatments and Functional Foods with Therapeutic Potential
AU - Gonçalves, Elisângela
AU - Smaoui, Slim
AU - Brito, Miguel
AU - Oliveira, J M
AU - Arez, Ana Paula
AU - Tavares, Loleny
N1 - Funding Information:
Miguel Brito gratefully acknowledges the FCT/MCTES national support through the projects H&TRC UIDB/05608/2020, UIDP/05608/2020, and IPL/IDI&CA2023/Ipasthma_ESTeSL. J.M. Oliveira acknowledges the financial support of CICECO\u2013Aveiro Institute of Materials, UIDB/50011/2020 (DOI 10.54499/UIDB/50011/2020), UIDP/50011/2020 (DOI 10.54499/UIDP/50011/2020) & LA/P/0006/2020 (DOI 10.54499/LA/P/0006/2020), financed by national funds through the FCT/MCTES (PIDDAC). Ana Paula Arez would like to acknowledge Funda\u00E7\u00E3o para a Ci\u00EAncia e a Tecnologia for funds to GHTM\u2014UID/04413/2020 and LA-REAL LA/P/0117/2020.
Publisher Copyright:
© 2024 by the authors.
PY - 2024/6/12
Y1 - 2024/6/12
N2 - Sickle cell anemia (SCA), the most common form of sickle cell disease (SCD), is a genetic blood disorder. Red blood cells break down prematurely, causing anemia and often blocking blood vessels, leading to chronic pain, organ damage, and increased infection risk. SCD arises from a single-nucleotide mutation in the β-globin gene, substituting glutamic acid with valine in the β-globin chain. This review examines treatments evaluated through randomized controlled trials for managing SCD, analyzes the potential of functional foods (dietary components with health benefits) as a complementary strategy, and explores the use of bioactive compounds as functional food ingredients. While randomized trials show promise for certain drugs, functional foods enriched with bioactive compounds also hold therapeutic potential. Further research is needed to confirm clinical efficacy, optimal dosages, and specific effects of these compounds on SCD, potentially offering a cost-effective and accessible approach to managing the disease.
AB - Sickle cell anemia (SCA), the most common form of sickle cell disease (SCD), is a genetic blood disorder. Red blood cells break down prematurely, causing anemia and often blocking blood vessels, leading to chronic pain, organ damage, and increased infection risk. SCD arises from a single-nucleotide mutation in the β-globin gene, substituting glutamic acid with valine in the β-globin chain. This review examines treatments evaluated through randomized controlled trials for managing SCD, analyzes the potential of functional foods (dietary components with health benefits) as a complementary strategy, and explores the use of bioactive compounds as functional food ingredients. While randomized trials show promise for certain drugs, functional foods enriched with bioactive compounds also hold therapeutic potential. Further research is needed to confirm clinical efficacy, optimal dosages, and specific effects of these compounds on SCD, potentially offering a cost-effective and accessible approach to managing the disease.
KW - bioactive compounds
KW - clinical trials
KW - functional food
KW - randomized
KW - sickle cell anemia
UR - http://www.scopus.com/inward/record.url?scp=85196879234&partnerID=8YFLogxK
U2 - 10.3390/cimb46060349
DO - 10.3390/cimb46060349
M3 - Review article
C2 - 38921020
SN - 1467-3037
VL - 46
SP - 5845
EP - 5865
JO - Current issues in molecular biology
JF - Current issues in molecular biology
IS - 6
ER -